1. Nanoparticles of a Pyrazolo-Pyridazine Derivative as Potential EGFR and CDK-2 Inhibitors: Design, Structure Determination, Anticancer Evaluation and In Silico Studies.
- Author
-
Hashem HE, Amr AEE, Almehizia AA, Naglah AM, Kariuki BM, Eassa HA, and Nossier ES
- Subjects
- Humans, Structure-Activity Relationship, Cell Proliferation, Cell Line, Tumor, ErbB Receptors metabolism, Amines pharmacology, Molecular Structure, Molecular Docking Simulation, Drug Screening Assays, Antitumor, Protein Kinase Inhibitors chemistry, Antineoplastic Agents chemistry, Pyridazines pharmacology, Nanoparticles
- Abstract
The strategic planning of this study is based upon using the nanoformulation method to prepare nanoparticles 4-SLNs and 4-LPHNPs of the previously prepared 4,5-diphenyl-1 H -pyrazolo[3,4- c ]pyridazin-3-amine ( 4 ) after confirming its structure with single crystal X-ray analysis. These nanoparticles exhibited promising cytotoxic activity against HepG-2, HCT-116 and MCF-7 cancer cell lines in comparison with the reference doxorubicin and the original derivative 4 . Moreover, their inhibitory assessment against EGFR and CDK-2/cyclin A2 displayed improved and more favorable impact than the parent 4 and the references. Detection of their influence upon cancer biomarkers revealed upregulation of Bax, p53 and caspase-3 levels and downregulation of Bcl-2 levels. The docking simulation demonstrated that the presence of the pyrazolo[3,4- c ]pyridazin-3-amine scaffold is amenable to enclosure and binding well within EGFR and CDK-2 receptors through different hydrophilic interactions. The pharmacokinetic and physicochemical properties of target 4 were also assessed with ADME investigation, and the outcome indicated good drug-like characteristics.
- Published
- 2023
- Full Text
- View/download PDF